Biosimilars Conference

Menu Back to Biosimilars-Conference

Overview

Conference | September 20-21

At the DIA Biosimilars Conference 2022, manufacturers, regulators, payers, prescribers, and patients will convene to discuss factors that influence biosimilar access and development and share perspectives on what success and progress looks like to provide cost-saving options for providers and patients in need

Attendees will apply practical solutions and forward-thinking learnings from around the world, to help build strategies for growth of the biosimilar’s market

Event Goals and Offerings
- Increase understanding of access to safe, effective, and cost-effective biological treatment options
- Collaborate with professionals in science, regulation, R&D, and more, to address barriers in biosimilar development
- Eliminate misinformation that delays policies to increase patient access
- Streamline global and regional goals with all stakeholder perspectives
Why You Can’t Miss It
- Increase potential of and access to the biosimilar’s market
- Meet and network with professionals involved in ongoing regulatory, manufacturing, pricing, and educational challenges
- Discuss influencing factors of biosimilar development by including stakeholders embedded in this space
- Apply the newest thinking and global learnings for strategic growth in biosimilar product development
- Incorporate viewpoints of manufacturers, regulators, payers, prescribers, and patients altogether
Learning Objectives

At the conclusion of this activity, participants should be able to:
- Discuss current developments in regulatory and scientific issues and their impact on development, manufacturing, access, and uptake of biosimilars and interchangeable products
- Discuss imperative and progress in streamlining biosimilar development
- Describe the impact of the approval of the first interchangeable biosimilar from a scientific and policy perspective
- Examine current prescriber and patient confidence and patterns of biosimilar use, and education efforts that have been successful in increasing literacy on these products
- Describe relevant international developments influencing patterns of biosimilar uptake globally
- Describe the status of biosimilar product development, availability, and uptake in the US
Meeting Designed For
- Biosimilar/Biologic/Biomedical R&D
- Chemistry, Manufacturing and Controls
- Regulatory Affairs
- (Non)Clinical Research
- Business & Data Development
- Marketing/Medical Communications
- Patient Advocacy/Patient Support Programs
- Health Education & Provision
- Quality Analysis & Management

Program Committee

Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States
Tiffany Fletcher, MA • Head of Global Access Policy
Viatris, United States
Denis Arsenault, MA • Manager, Policy Development
Health Canada, Canada
Mauricio Ede, MD, PhD • Chief Medical & Scientific Officer
Sandoz Canada Inc., Canada
Stanton Mehr • Director of Content
Biosimilars Review and Report, United States
Juliana Marguerite Reed, MS • Executive Director
The Biosimilars Forum, United States
Stacey Ricci, DrSc • Director, Scientific Review Staff, OTBB, OND, CDER
FDA, United States
Cecil J. Nick, MS • FTOPRA, Vice President (Technical)
Parexel Consulting, United Kingdom